Agilent Q4 Revenues Slip 3 Percent but Beats Analyst Estimates on Top, Bottom Lines | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies said after the close of the market on Thursday that revenues for its fiscal fourth quarter were down 3 percent year over year, but the company still beat the average analyst estimate on the top and bottom lines.

For the three months ended Oc. 31, Agilent's total revenues dipped to $1.72 billion, compared to $1.77 billion a year ago, edging out the consensus Wall Street estimate of $1.71 billion.

The company had $1.83 billion in orders, up almost 5 percent from $1.75 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.